Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking and Finance Review

Global Banking and Finance Review - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Finance > Novartis to pay Matchpoint up to $1 billion to develop anti-inflammatory therapies
    Finance

    Novartis to pay Matchpoint up to $1 billion to develop anti-inflammatory therapies

    Published by Global Banking and Finance Review

    Posted on July 24, 2025

    1 min read

    Last updated: January 22, 2026

    Novartis to pay Matchpoint up to $1 billion to develop anti-inflammatory therapies - Finance news and analysis from Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Tags:innovationpartnershipresearchBiotechhealthcare

    Quick Summary

    Novartis partners with Matchpoint Therapeutics in a deal worth up to $1 billion to develop oral drugs for inflammatory diseases, with potential global commercialization rights.

    Novartis to pay Matchpoint up to $1 billion to develop anti-inflammatory ther...

    (Reuters) -Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs for several inflammatory diseases.

    Matchpoint said on Thursday it will use its technology to develop drugs that block the activity of a specific protein, helping to lower the production of inflammation-causing signals.

    The company will lead the research and drug development process, using the funding from Novartis.

    If Novartis exercises its option to exclusively license the program, the drugmaker will have global rights to develop and commercialize all products resulting from the collaboration.

    Matchpoint said it will receive up to $60 million in upfront payment and research funding, with up to $1 billion in total potential payments, including option exercise fee, and development and commercial milestones.

    (Reporting by Christy Santhosh in Bengaluru; Editing by Sriraj Kalluvila and Shinjini Ganguli)

    Key Takeaways

    • •Novartis to invest up to $1 billion in Matchpoint.
    • •Focus on developing oral drugs for inflammatory diseases.
    • •Matchpoint to lead research and development efforts.
    • •Novartis may obtain global commercialization rights.
    • •Initial $60 million in upfront payment and research funding.

    Frequently Asked Questions about Novartis to pay Matchpoint up to $1 billion to develop anti-inflammatory therapies

    1What is the total potential payment Novartis will make to Matchpoint?

    Novartis will pay up to $1 billion to Matchpoint Therapeutics, which includes an upfront payment and research funding.

    2What type of therapies will Matchpoint develop with Novartis's funding?

    Matchpoint will develop oral drugs targeting several inflammatory diseases by blocking the activity of a specific protein.

    3What rights will Novartis have if they exercise their option?

    If Novartis exercises its option, it will have global rights to develop and commercialize all products resulting from the collaboration.

    4How much will Matchpoint receive upfront?

    Matchpoint will receive up to $60 million in upfront payment and research funding from Novartis.

    5Who is reporting on this collaboration?

    The article is reported by Christy Santhosh in Bengaluru, with editing by Sriraj Kalluvila and Shinjini Ganguli.

    More from Finance

    Explore more articles in the Finance category

    Image for Pandora sees 2026 organic revenue growth at -1% to 2%
    Pandora sees 2026 organic revenue growth at -1% to 2%
    Image for Telegram's Durov says proposed Spanish social media restrictions seek to censor critics
    Telegram's Durov says proposed Spanish social media restrictions seek to censor critics
    Image for Dip-buyers go missing as software selloff slams stocks
    Dip-buyers go missing as software selloff slams stocks
    Image for Europe's anti-money laundering body set to be fully operational in 2028
    Europe's anti-money laundering body set to be fully operational in 2028
    Image for Dental sector may steady in 2026, but full recovery remains distant, analysts say
    Dental sector may steady in 2026, but full recovery remains distant, analysts say
    Image for Rio Tinto seeks leadership roles in Glencore merger talks, FT says
    Rio Tinto seeks leadership roles in Glencore merger talks, FT says
    Image for Exclusive-EU rethinks climate diplomacy after bruising COP30 summit, document shows
    Exclusive-EU rethinks climate diplomacy after bruising COP30 summit, document shows
    Image for SAS in talks with Boeing and Airbus on widebody order, Bloomberg News reports
    SAS in talks with Boeing and Airbus on widebody order, Bloomberg News reports
    Image for Automakers back Trump plan to roll back fuel economy rules, but seek changes
    Automakers back Trump plan to roll back fuel economy rules, but seek changes
    Image for Serbia seeks EU gas deals as it reduces Russian supplies, says President Vucic
    Serbia seeks EU gas deals as it reduces Russian supplies, says President Vucic
    Image for Germany's Merz heads to Saudi, Gulf in quest for new partners
    Germany's Merz heads to Saudi, Gulf in quest for new partners
    Image for Stellantis faces Peugeot model delays due to battery plant issues, Bloomberg News reports
    Stellantis faces Peugeot model delays due to battery plant issues, Bloomberg News reports
    View All Finance Posts
    Previous Finance PostItaly's MPS focused on Mediobanca deal, CEO says after UniCredit drops BPM bid
    Next Finance PostEU starts surveillance of scrap metal trade as supplies decline